update on sarcomas rare bone sarcomas

UPDATE ON SARCOMAS

Rare bone sarcomas

Silvia [email protected]

Do not duplicate or d

istribute without

permiss

ion from author a

nd ESO

DISCLOSURES

Personal financial interests (honoraria, consultancy or advisory role): Adaptimmune, Bayer, Epizyme, Eli Lilly, Daiichi Sankyo, Immunedesign, Karyopharm, Maxivax, Pharmamar, Takeda

Institutional financial interests: Amgen Dompè, Bayer, Epizyme, Eli Lilly, Daiichi Sankyo, Novartis, Pfizer, Pharmamar


istribute without

permiss

ion from author a

nd ESO

Cartilage tumours

• Chondrosarcoma

• Dedifferentiated chondrosarcoma

• Mesenchymal chondrosarcoma

• Clear cell chondrosarcoma

Fibrogenic tumours

Fibrohistiocitic tumours

Giant cell tumours

• Giant cell tumor

• Malignancy in giant cell tumours

Notochordal tumours

• Chordoma

Vascular tumours

• Haemangioma and related lesion

• Angiosarcoma

Myogenic, lipogenic, neural and epithelial

tumours

• Leiomyosarcoma of bone

• Liposarcoma of bone

• ...

Congenital snd inherited syndromes

• Enchondromatosis (Ollier/Maffucci

Syndrome)

• ...


istribute without

permiss

ion from author a

nd ESO

Sbaraglia M et al, CTOS 2018


istribute without

permiss

ion from author a

nd ESO


427 primary vascular tumors diagnosed at IOR (Bologna)

since 1937 (90 yrs!)

289 hemangiomas

183 sarcomas (32%)

52 (12%) angiosarcomas (45 epithelioid)

38 (8.9%) epithelioid hemangiomas

24 (5.6%) pseudomyogenic hemangioendotheliomas

21 (5.2%) epithelioid hemangioendotheliomas

2 retiform hemangioendotheliomas


istribute without

permiss

ion from author a

nd ESO


Primary tumors

Recurrence free survival


istribute without

permiss

ion from author a

nd ESO


Primary tumors

Overall survival


istribute without

permiss

ion from author a

nd ESO

SFT

leio

…

CHEMOSENSITIVITY: THE SAME AS THE

SOFT TISSUE COUNTERPART

?Do not duplicate or d

istribute without

permiss

ion from author a

nd ESO

Chordoma

bone tumor

mesenchymal/epithelial differentiation

0.8/1.000.000

(benign lesion 20%)

600-750 pts/yr in EU

indolent clinical behaviourDo not duplicate or d

istribute without

permiss

ion from author a

nd ESO

Age ▪ Median age 60 yrs

A Trama, Sept 2017


istribute without

permiss

ion from author a

nd ESO

Pathology

▪ Conventional chordoma (>95%)

nuclear staining for brachyury

▪ Dedifferentiated chordoma (<5%)

▪ Poorly differentiated chordoma (<5%)Do not duplica

te or distr

ibute without

permiss

ion from author a

nd ESO

INI1 loss and negative nuclear staining of

brachyury

DEDIFFERENTIATEDCHORDOMA

H&E

MIB

1

BRY

INI1


istribute without

permiss

ion from author a

nd ESO

Images courtesy of Dr. Mrinal Gounder

H&E Brachyury INI1

POORLY DIFFERENTIATED CHORDOMA

CHILDREN (0-21 YRS)Do not duplica

te or distr

ibute without

permiss

ion from author a

nd ESO

wide excision +/- HD-RT

or

- unresected cases -

definitive HD-RT

Primary tumor


istribute without

permiss

ion from author a

nd ESO

Relapsed chordoma

Ann Oncol 2017


istribute without

permiss

ion from author a

nd ESO

Ann Oncol 2017

Relapsed chordoma


istribute without

permiss

ion from author a

nd ESO

Ann Oncol 2017

“Medical therapy is an appropriate palliative option for patients whose disease is actively progressing or who are symptomatic

A brief observation period may be warranted before starting medical therapy to determine whether, and at

what rate, progressing “

Relapsed chordoma


istribute without

permiss

ion from author a

nd ESO

No active drug formally approved


istribute without

permiss

ion from author a

nd ESO

No active drug formally approved

the compassionate and off-label use

of new drugs

is widespread in chordoma

with

a very discordant access

to potentially active treatments

among different European countriesDo not duplica

te or distr

ibute without

permiss

ion from author a

nd ESO

Overall <10% RECIST PRreported in literature


istribute without

permiss

ion from author a

nd ESO

Medical Treatment, chemo

cytotoxic

chemotherapy

“However, anecdotal reports of responses to anthracyclines,

cisplatin, alkylating agents, etoposide

in high-grade dedifferentiated and pediatric cases”

Stacchiotti S et al, Lancet Oncol 2015Ann Oncol 2017


istribute without

permiss

ion from author a

nd ESO

S David et al, CTOS 2018

Medical Treatment, chemo


istribute without

permiss

ion from author a

nd ESO

+3 mosbaseline

CDDPDo not duplicate or d

istribute without

permiss

ion from author a

nd ESO

” At present,

imatinib and sorafenib

are the medical therapies with the greatest evidence of antitumor

activity in chordoma and represent reasonable palliative treatment

options to slow disease progression or alleviate symptoms”

Ann Oncol 2017

Medical Treatment, TKI


istribute without

permiss

ion from author a

nd ESO

RECIST

PR = 1 pt (2%)minor response 9 (18%)

SD = 35 pts (70%)

PD = 14 pts (28%)

mPFS = 9 mos

Stacchiotti S et al, JCO 2012

Imatinib


istribute without

permiss

ion from author a

nd ESO

Baseline

2 mos

6 mos

18 mos+


istribute without

permiss

ion from author a

nd ESO

Bompas E et al, Ann Oncol 2015

RECIST

PR = 1/27

9-mo PFS 73.0%

12-mo OS 86.5%

Sorafenib


istribute without

permiss

ion from author a

nd ESO

Stacchiotti S et al, Eur J Cancer 2018

Imatinib + everolimus

40 evaluable pts, all progressive

imatinib 400 mg + everolimus 2.5 mg

Choi

PR 9/40 (ORR 20.9%)

RECIST

1 PR


istribute without

permiss

ion from author a

nd ESO





Choi

PR 9/40 (ORR 20.9%)

RECIST

1 PR

m-PFS (Choi) 11.5 mos

m-PFS (RECIST) 14 mos


istribute without

permiss

ion from author a

nd ESO





Choi

PR 9/40 (ORR 20.9%)

RECIST

1 PR

m-PFS (Choi) 11.5 mos

m-PFS (RECIST) 14 mos

30% definitive interruption for toxicity

S6/4EBP1 phosphorylated in a high and

moderate/low proportion of tumor cells in

responsive and nonresponsive patientsDo not duplica

te or distr

ibute without

permiss

ion from author a

nd ESO

Sunitinib/ Pazopanib

Lipplaa A et al, Clin Sarc Res 2017


istribute without

permiss

ion from author a

nd ESO

Launay SG, BMC Cancer 2011

… erlotinibcetuximab

gefitinib

EGFR inhibitors


istribute without

permiss

ion from author a

nd ESO

Open trials


istribute without

permiss

ion from author a

nd ESO

Magnaghi P et al, Mol Cancer Ther 2018

IC50 (uM)

Compound UCH-1UCH-2

(Ch. F.)

UCH-2

(ATCC)Chor-IN-1

MUG-

Chor1JHC7

A2780

ctrl

EGFR1

Biochemical1

Afatinib 0.010 0.208 0.257 0.586 0.260 1.726 2.114 0.001

Neratinib 0.021 1.894 3.756 1.903 2.152 2.944 0.491 0.008

Erlotinib 0.137 6.297 6.885 1.917 2.615 1.712 3.447 0.005

Ibrutinib 0.388 5.600 4.770 9.319 > 10 3.655 3.463 0.021

Lapatinib 0.554 > 10 > 10 > 10 > 10 > 10 3.076 0.030

Gefitinib 0.608 3.418 5.133 8.650 6.787 7.133 4.990 0.004

Vandetanib 1.195 1.948 4.618 4.460 3.654 7.207 1.502 0.039

Rociletinib/CO-1686 2.115 2.650 3.176 0.897 4.615 2.670 0.915 0.535

Open trial, afatinib


istribute without

permiss

ion from author a

nd ESO

Advanced, progressing

chordoma

Afatinib

40 mg/day

Continue

up to progression

and/or toxicity

Open trials, afatinib


istribute without

permiss

ion from author a

nd ESO

Images courtesy of Dr. Mrinal Gounder

H&E Brachyury INI1

POORLY DIFFERENTIATED CHORDOMA

CHILDREN (0-21 YRS)

Open trials, tazemetostat


istribute without

permiss

ion from author a

nd ESO


TAZEMETOSTAT


istribute without

permiss

ion from author a

nd ESO



istribute without

permiss

ion from author a

nd ESO

CHILDREN (0-23 YRS)



istribute without

permiss

ion from author a

nd ESO

REGOBONE

Open trials, regorafenib


istribute without

permiss

ion from author a

nd ESO

Von Witlzleben et al, Cancer Res 2015

Open trials, palbociclib


istribute without

permiss

ion from author a

nd ESO

Migliorini D et al, Oncoimmunology 2017

Open trials, vaccine


istribute without

permiss

ion from author a

nd ESO

Chondrosarcoma


istribute without

permiss

ion from author a

nd ESO

▪ Conventional (85%)

▪ Dedifferentiated

H3K27me3 deficiency

▪Mesenchymal

HEY1-NCOA2

▪ Clear Cell

▪ Extraskeletal Myxoid Chondrosarcoma

Pathology


istribute without

permiss

ion from author a

nd ESO

wide excision +/- HD-RT

or

- unresected cases -

definitive HD-RT

Primary tumor


istribute without

permiss

ion from author a

nd ESO

Relapsed bone chondrosarcoma

limited chemosensitivity

to cytotoxicsDo not duplicate or d

istribute without

permiss

ion from author a

nd ESO

baseline

+ 4 mos

doxo

doxo, conventional/ dediff/ mesenchymal chondro


istribute without

permiss

ion from author a

nd ESO

- 3 mos

baseline

+ 4 mos

gemcitabine

PD

gemcitabine,

conventional chondro


istribute without

permiss

ion from author a

nd ESO

trabectedin,mesenchymal chondro

Morioka H et al, BMC Cancer 2016


istribute without

permiss

ion from author a

nd ESO

antiangiogenics

Jones et al., Mod Oncol 2017


istribute without

permiss

ion from author a

nd ESO

REGOBONE

Open trial, regorafenib


istribute without

permiss

ion from author a

nd ESO


istribute without

permiss

ion from author a

nd ESO

Tawbi et al, Lancet Oncol 2017

Pembrolizumab

RECIST

PR = 1/5 ptminor response (<30%) 0


istribute without

permiss

ion from author a

nd ESO

Martin Broto J et al, ASCO 2018

Sunitinib + nivolumab


istribute without

permiss

ion from author a

nd ESO

bone tumor

mesenchymal/epithelial differentiation

synonym: osteoclastoma

4-5% of all primary bone tumor

Paget-related cases

>20-45 yrs

F>M

benign, locally aggressive

malignant transformation

Giant Cell Tumor of Bone


istribute without

permiss

ion from author a

nd ESO

Behjati S et al, Nature Genetics 2013

point mutations of

H3F3A gene

- coding for a histone H3.3

protein -

Pathology


istribute without

permiss

ion from author a

nd ESO

Behjati S et al, Nature Genetics 2013Righi A, Human Path 2017

Pathology


istribute without

permiss

ion from author a

nd ESO

Cartilage tumours

• Chondrosarcoma

• Dedifferentiated chondrosarcoma

• Mesenchymal chondrosarcoma

• Clear cell chondrosarcoma

Fibrogenic tumours

Fibrohistiocitic tumours

Giant cell tumours

• Giant cell tumour

• Malignancy in giant cell tumour

Notochordal tumours

• Chordoma

Vascular tumours

• Haemangioma and related lesion

• Angiosarcoma

Myogenic, lipogenic, neural and epithelial

tumours

• Leiomyosarcoma of bone

• Liposarcoma of bone

• ...

Congenital snd inherited syndromes

• Enchondromatosis (Ollier/Maffucci

Syndrome)

Fletcher C et al, WHO 2013

Pathology


istribute without

permiss

ion from author a

nd ESO

“benign but locally aggressive primary bone neoplasm”


Pathology


istribute without

permiss

ion from author a

nd ESO

mononuclear stromal spindle cells

macrophage osteoclast-like giant round multinuclear cell

RANKL is expressed by stromal tumor cell

RANK is expressed by giant osteoclast-like cells


istribute without

permiss

ion from author a

nd ESO

Metastases can have

benign path aspects


istribute without

permiss

ion from author a

nd ESO

“A high-grade malignant neoplasm arising in GCT may be

identified at initial diagnosis (ie primary malignancy in

GCT) or at relapse (secondary malignancy in GCT)”


Pathology


istribute without

permiss

ion from author a

nd ESO

“Primary malignancy in GCT refers to cases where an area or nodule of

highly pleomorphic mononuclear cells is present in an otherwise

conventional GCT. The transition between the two components varies.

The high-grade sarcoma has no specific morphology; it may or may not

produce osteoid. In secondary malignancy in GTC, the pre-existing GCT

may or may not be evident”

Pathology



istribute without

permiss

ion from author a

nd ESO


istribute without

permiss

ion from author a

nd ESO

Folpe AL et al. Mod Pathol 1999

Pathology


istribute without

permiss

ion from author a

nd ESO

surgery

recurrence rate:complete resection: 10-20%

curretage: > 60%

2-5% metastases (>lung)

Primary tumor


istribute without

permiss

ion from author a

nd ESO

Malignancy in GTC incidence

▪ 1-3% high-grade sarcoma dedifferentiation

Saada et al, JCO 2011


istribute without

permiss

ion from author a

nd ESO

Critical sites requiring demolitive surgery

(benign GCT)

Medical therapy, when?


istribute without

permiss

ion from author a

nd ESO

Critical sites requiring demolitive surgery

(benign GCT)

Metastatic cases

«Benign»

Malignant GCT

Medical therapy, when?


istribute without

permiss

ion from author a

nd ESO

Denosumab


istribute without

permiss

ion from author a

nd ESO

Bransletter et al, Clin Cancer Res 2012

Denosumab, path response


istribute without

permiss

ion from author a

nd ESO

282 pts

9/2008-3/2011

Chawla et al, Lancet Oncol 2013

PD: 8/282 pts (3%)

RECIST ORR: 41%

Denosumab


istribute without

permiss

ion from author a

nd ESO

ADVERSE EVENTS OF INTEREST N=526 (%)

Osteonecrosis of the jaw 28 (5%)

Palmerini E et al, ESMO 2017, 2740067

Denosumab


istribute without

permiss

ion from author a

nd ESO



Atypical femur fracture 4 (1%)

New malignancy in GCTB

•Primary malignant

•Secondary malignant

•Sarcomatous transformation

10 (2%)

5 (1%)

1

4


Denosumab


istribute without

permiss

ion from author a

nd ESO



Atypical femur fracture 4 (1%)

New malignancy in GCTB

•Primary malignant

•Secondary malignant

•Sarcomatous transformation

10 (2%)

5 (1%)

1

4

≥ Grade 3 hypercalcemia (following

discontinuation)

4 (1%)


Denosumab


istribute without

permiss

ion from author a

nd ESO

0

+ 6 months

+ 24 months

Denosumab


istribute without

permiss

ion from author a

nd ESO

0 + 6 months

Denosumab


istribute without

permiss

ion from author a

nd ESO

0

+ 1 month

+ 6 months

Denosumab


istribute without

permiss

ion from author a

nd ESO

0 + 3 months

Denosumab


istribute without

permiss

ion from author a

nd ESO

Treatment duration?

Which is the best surgical approach after d’mab?

Relapse-free survival after d’mab + surgery?

Denosumab, open issues


istribute without

permiss

ion from author a

nd ESO

Which medical therapy in

sarcoma in GCTB?

0

+ 5 cycles

Epi-Ifx


istribute without

permiss

ion from author a

nd ESO

Silvia Stacchiotti

[email protected]


istribute without

permiss

ion from author a

nd ESO

http://www.google.it/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&docid=2_gKXQuRe7GghM&tbnid=PQlkNAuzB5NUHM:&ved=0CAcQjRw&url=http://www.istitutotumori.mi.it/modules.php?name%3DContent%26pa%3Dshowpage%26pid%3D286&ei=dtEjVM_oKIXd7Qa3qYCQBw&bvm=bv.76247554,d.ZGU&psig=AFQjCNGf1aFf-83EbTnxR6oH9xj0Z5RLZA&ust=1411719912686811

Bone SFT


istribute without

permiss

ion from author a

nd ESO

COHORT 1 – unresectable GCTB

COHORT 2 – resectable GCTB

• 5-yr PFS 88%

• 67% surgery

• 5-yr EFS 88%

• 44% less extensive surgery

• 27% relapses


CURRETTAGE vs RESECTION

34% vs 12%


Denosumab


istribute without

permiss

ion from author a

nd ESO

CTOS 2013, ChicagoDo not duplica

te or distr

ibute without

permiss

ion from author a

nd ESO

update on sarcomas rare bone sarcomas

Documents